<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <title>Best Of Week - Head &amp; Neck Cancer</title>
    <link>https://pubmed.ncbi.nlm.nih.gov</link>
    <description>Top 10 most impactful head and neck cancer papers this week, selected by AI</description>
    <lastBuildDate>Wed, 14 Jan 2026 07:03:27 +0000</lastBuildDate>
    <item>
      <title>#1 [90/100] Is proton therapy a new standard of care for oropharyngeal cancer?</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41519583/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41519583/</guid>
      <dc:creator>Jensen K, Grau C</dc:creator>
      <pubDate>Sat, 10 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;üî• CRITICAL - Score: 90/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; The paper discusses proton therapy for oropharyngeal cancer in a high-impact journal, suggesting potential practice-changing implications for a common cancer type, likely addressing significant clinical questions with robust evidence.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Jensen K, Grau C&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Lancet (London, England) | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/S0140-6736(25)02639-X'&gt;10.1016/S0140-6736(25)02639-X&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-10&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41519583/'&gt;41519583&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;i&gt;No abstract available&lt;/i&gt;</description>
    </item>
    <item>
      <title>#2 [82/100] Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41530380/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41530380/</guid>
      <dc:creator>Yap TA, Sweis RF, Vaishampayan U, Kilari D, Gainor JF, McKean M, Barve M, Tarhini AA, Bockorny B, Sonpavde G, et al.</dc:creator>
      <pubDate>Tue, 13 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚≠ê HIGH IMPACT - Score: 82/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This phase 1 trial evaluates a first-in-class therapy combined with pembrolizumab in immune checkpoint blockade-resistant tumors, showing potential for significant clinical benefit and addressing unmet needs in oncology, published in a top-tier journal.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Yap TA, Sweis RF, Vaishampayan U, Kilari D, Gainor JF, McKean M, Barve M, Tarhini AA, Bockorny B, Sonpavde G, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Nature medicine | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1038/s41591-025-04157-w'&gt;10.1038/s41591-025-04157-w&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-13&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41530380/'&gt;41530380&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;Although immune checkpoint inhibitor therapies have revolutionized oncology, many cancers are unresponsive or develop resistance that involves transforming growth factor-Œ≤1 (TGFŒ≤1). This multicenter, open-label, phase 1 study (DRAGON trial, SRK-181-001) evaluated safety, pharmacokinetics, pharmacodynamics, predictive biomarkers and efficacy of linavonkibart, a first-in-class fully human selective anti-latent TGFŒ≤1 antibody with anti-programmed cell death protein 1 (PD-1) therapy. The DRAGON trial was divided into three treatment parts: part A1 (dose-escalation cohorts with single-agent linavonkibart), part A2 (dose-escalation cohorts with the combination treatment of linavonkibart and pembrolizumab) and part B (dose-expansion cohorts with the combination treatment). The primary objective of the study was to determine the safety and tolerability of linavonkibart alone and in combination with pembrolizumab. Secondary objectives included evaluation of linavonkibart pharmacokinetics for each treatment paradigm, assessment of anti-linavonkibart antibody development (parts A and B) and measurement of antitumor activity (part B) after treatment. All primary and secondary objectives were met in the study. Overall, linavonkibart had a manageable safety profile, and combined therapy with pembrolizumab was generally consistent with that of pembrolizumab monotherapy. Dermatological reactions were the only additional risk identified. Neither cytokine release syndrome nor infusion interruption was observed in any patient enrolled in DRAGON. In part A (n‚Äâ=‚Äâ34), no dose-limiting toxicities or grade 4 or 5 treatment-related adverse events occurred (linavonkibart; ‚â§3,000‚Äâmg once every 3‚Äâweeks (Q3W) and 2,000‚Äâmg once every 2‚Äâweeks (Q2W)). In part B (n‚Äâ=‚Äâ78), patients progressing on prior anti-PD-1 therapy received linavonkibart (1,500‚Äâmg Q3W/1,000‚Äâmg Q2W) with pembrolizumab (200‚Äâmg Q3W). This combination demonstrated confirmed objective response rates of 20.0%, 18.2%, 9.1% and 9.1% in anti-PD-1-resistant patients with clear cell renal cell cancer (ccRCC), melanoma, head and neck squamous cell cancer and urothelial cancer, respectively. Biomarker data provide proof of mechanism and a potential ccRCC patient selection strategy. ClinicalTrials.gov identifier: NCT04291079 .</description>
    </item>
    <item>
      <title>#3 [75/100] Oncologic Outcomes of Transoral Robotic Surgery in HPV-Associated OPSCC: A Systematic Review and Meta-Analysis.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41521853/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41521853/</guid>
      <dc:creator>Cheung MH, Kim CH, Nguyen SA, Williamson L, Kejner A, Bobian M, Newman JG</dc:creator>
      <pubDate>Mon, 12 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This systematic review and meta-analysis includes a substantial number of studies and patients (n=16,129), providing important insights into oncologic outcomes of TORS for HPV-associated OPSCC, which could influence clinical practice, though it is not a randomized controlled trial.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Cheung MH, Kim CH, Nguyen SA, Williamson L, Kejner A, Bobian M, Newman JG&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/ohn.70101'&gt;10.1002/ohn.70101&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-12&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41521853/'&gt;41521853&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;OBJECTIVE: To define survival and recurrence outcomes of HPV associated oropharyngeal squamous cell carcinoma (OPSCC) following transoral robotic surgery (TORS). DATA SOURCES: PubMed, Scopus, CINAHL. REVIEW METHODS: A systematic review and meta-analysis were performed on studies employing TORS in HPV-associated OPSCC. Meta-analysis of continuous measures, proportions, and comparison of weighted proportion and relative risk were performed for patient characteristics and outcomes. RESULTS: A total of 58 studies, comprising 16,129 adults treated with TORS for OPSCC, were included. The mean age was 59.5 years (SD 2.08) (range 18-93), with an average follow-up of 43.4 months (SD 13.36); 83.5% of the cohort was male, and 85.6% had HPV-positive OPSCC. In the HPV-positive group, TORS survival rates were 91.0% at 1 year, 94.9% at 3 years, and 89.8% at 5 years. In comparison, the HPV-negative group had survival rates of 92.3%, 84.2%, and 72.9%, respectively. Significant survival differences were observed between cohorts at 3 and 5 years (P‚Äâ&lt;‚Äâ.0001). The HPV-positive group had a significantly higher likelihood of 5-year overall survival compared to the HPV-negative group (RR‚Äâ=‚Äâ1.18, 95% CI: 1.05-1.34) Recurrence rates in HPV-positive patients were 2.0% local, 3.1% regional, and 5.3% locoregional, whereas HPV-negative patients had recurrence rates of 7.6% local, 6.0% regional, and 9.1% locoregional (P‚Äâ=‚Äâ.0037, .2143, .426, respectively). Distant metastasis rates were 5.6% in HPV-positive and 10.2% in HPV-negative patients (P‚Äâ=‚Äâ.0033). CONCLUSION: The higher survival rates and lower recurrences in HPV-positive OPSCC patients compared to their HPV-negative counterparts reflects the favorable long-term oncologic outcome seen in HPV-associated OPSCC.</description>
    </item>
    <item>
      <title>#4 [75/100] Auditory Preservation in Nasopharyngeal Carcinoma: Comparison of Proton and Photon Radiotherapy.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41503873/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41503873/</guid>
      <dc:creator>Lien KH, Lin CY, Chen PY, Chang JT, Chen TY, Hung SP, Lee CH, Yap WK, Hsieh CE, Hsu CL, et al.</dc:creator>
      <pubDate>Thu, 08 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study is a prospective matched cohort analysis comparing two radiotherapy techniques in a significant patient population, with potential implications for auditory preservation in nasopharyngeal carcinoma, although it is not a randomized controlled trial.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Lien KH, Lin CY, Chen PY, Chang JT, Chen TY, Hung SP, Lee CH, Yap WK, Hsieh CE, Hsu CL, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/ohn.70113'&gt;10.1002/ohn.70113&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-08&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41503873/'&gt;41503873&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;OBJECTIVE: To compare cochlear dose and hearing outcomes between intensity-modulated proton therapy (IMPT) and volumetric modulated arc therapy (VMAT) in patients with nasopharyngeal carcinoma (NPC). STUDY DESIGN: Prospective matched cohorts. SETTING: Tertiary academic center. METHODS: A total of 180 newly diagnosed, treatment-naive NPC patients receiving definitive radiotherapy between 2023 and 2025 were enrolled. Patients were 1:1 matched by sex, age, and disease stage, and assigned to IMPT (n‚Äâ=‚Äâ90) or VMAT (n‚Äâ=‚Äâ90). Mean cochlear dose was recorded. Audiological evaluations, including pure-tone audiometry (PTA), air-bone gap, and word recognition score, were performed before and after treatment. RESULTS: IMPT delivered significantly lower mean doses to the ipsilateral (47.51 vs 56.82‚ÄâGy, P‚Äâ&lt;‚Äâ.001; 95% CI: -14.27 to -4.35) and contralateral cochlea (30.79 vs 45.71‚ÄâGy, P‚Äâ&lt;‚Äâ.001; 95% CI: -18.93 to -10.91). Based on each patient's most recent audiometric assessment (median follow-up, 12.1 months; range, 7.5-19.5 months), IMPT demonstrated better average PTA thresholds than VMAT (33.72 vs 42.00‚ÄâdB; P‚Äâ=‚Äâ.016; 95% CI, -14.91 to -1.65), superior high-frequency hearing at 2 to 8‚ÄâkHz (37.94 vs 53.82‚ÄâdB; P‚Äâ&lt;‚Äâ.001; 95% CI, -23.69 to -8.07), lower air-bone gap (5.67 vs 10.62‚ÄâdB; P‚Äâ&lt;‚Äâ.001; 95% CI, -6.80 to -3.10), and higher word recognition scores (96.67% vs 94.00%; P‚Äâ=‚Äâ.039; 95% CI, 0.14-5.20), with less bone conduction loss at 1 to 4‚ÄâkHz. CONCLUSION: IMPT reduces cochlear dose compared to VMAT, resulting in better hearing preservation and suggesting its potential to minimize ototoxicity in NPC patients.</description>
    </item>
    <item>
      <title>#5 [70/100] Stereotactic Body Radiation Therapy With Pembrolizumab in PD-1 Inhibitor Refractory, Recurrent or Metastatic, Head and Neck Squamous Cell Carcinoma: A Phase 2 Trial.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41520892/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41520892/</guid>
      <dc:creator>So J, Droznin A, Tiwari P, Chen YH, Chau N, Margalit DN, Tishler RB, Hanna GJ, Mak RH, Fitzgerald K, et al.</dc:creator>
      <pubDate>Fri, 09 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This is a prospective phase 2 trial evaluating a combination therapy in a challenging patient population, which could provide important insights into treatment options for PD-1 refractory head and neck cancer, though it lacks the robust evidence of a randomized controlled trial.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; So J, Droznin A, Tiwari P, Chen YH, Chau N, Margalit DN, Tishler RB, Hanna GJ, Mak RH, Fitzgerald K, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; International journal of radiation oncology, biology, physics | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.ijrobp.2025.12.043'&gt;10.1016/j.ijrobp.2025.12.043&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-09&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41520892/'&gt;41520892&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;PURPOSE: To evaluate the safety, feasibility, and clinical efficacy of stereotactic body radiation therapy (SBRT) combined with pembrolizumab in patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed on prior PD-1 inhibitor therapy. METHODS AND MATERIALS: This prospective, non-randomized phase II trial enrolled patients with PD-1 inhibitor-refractory R/M HNSCC. In Cohort A, a single lesion was treated with SBRT while other sites were left unirradiated. In Cohort B, all known oligometastatic lesions were treated with SBRT. Pembrolizumab was administered every 3 weeks in both cohorts. The primary endpoint was 3-month progression-free survival (PFS). Correlative immune analyses were performed on peripheral blood mononuclear cells using mass cytometry and TCRŒ≤ sequencing. RESULTS: Eighteen patients were treated (6 in Cohort A, 12 in Cohort B). Median PFS was 1.8 months in Cohort A and 5.7 months in Cohort B. The 3-month PFS rate was 17% (1/6) in Cohort A and 67% (8/12) in Cohort B, with an overall response rate of 25% (3/12) in Cohort B and no objective responses in Cohort A. Median OS was 7.6 months (95% CI: [0.7-32.9])in Cohort A and 10.1 months (95% CI: [5.8-49.7]) in Cohort B. In Cohort B there were 2 (2/12, 17%) Grade 4 toxicities observed in the setting of re-irradiation. Correlative studies showed that patients with PFS &gt;3 months had higher baseline frequencies of CD8+ central memory T cells and elevated CXCR5 expression on memory B cells. CONCLUSIONS: In anti PD-1-refractory R/M HNSCC, SBRT with pembrolizumab was safe and feasible, suggesting activity when all progressing lesions were treated. Immune profiling describes pre-existing memory T and B cell phenotypes that appear to correlate with treatment benefit. These findings support further study and clinical use of comprehensive SBRT plus PD-1 blockade in this hard-to-treat population.</description>
    </item>
    <item>
      <title>#6 [70/100] Single vocal cord irradiation (SVCI) vs whole laryngeal radiotherapy in the treatment of T1aN0 glottic cancer A prospective randomized trial.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41520731/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41520731/</guid>
      <dc:creator>Elsharief MM, Hassouna AH, Shouman T, Mosallam A, Elbadrawy A, Shawky A, Wahab AA, Abdelfatah SM</dc:creator>
      <pubDate>Fri, 09 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This is a prospective phase 2 randomized trial comparing two radiotherapy techniques for T1aN0 glottic cancer, providing valuable insights into treatment outcomes and toxicity, though the sample size is relatively small.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Elsharief MM, Hassouna AH, Shouman T, Mosallam A, Elbadrawy A, Shawky A, Wahab AA, Abdelfatah SM&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.radonc.2026.111376'&gt;10.1016/j.radonc.2026.111376&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-09&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41520731/'&gt;41520731&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;INTRODUCTION: Both Transoral laser surgery (TLS) and radiotherapy are used in the treatment of T1aN0 glottic cancer with similar oncological outcomes. Retrospective studies suggest excellent local control with single vocal cord irradiation that targets only the affected vocal cord. So, the aim of this study was to compare the treatment outcome and toxicity of the classic radiotherapy field vs single vocal cord irradiation (SVCI) technique. PATIENTS AND METHODS: This is a prospective phase 2 randomized study (clinicaltrial.gov registration NCT05679856). A total of 57 patients with T1aN0 glottic cancer were randomized. 28 were assigned to standard of care whole larynx radiotherapy that covers the whole larynx with a prescription dose of 63‚ÄØGy/28 Fractions (Fs) The remaining 29 patients were randomized to single vocal irradiation with a prescription dose of 58.08‚ÄØGy/16Fs. The primary endpoint was to prove superiority of SVCI in terms of voice quality by comparing voice handicap index (VHI) between the 2 study arms. Baseline VHI was recorded before treatment, at end of radiotherapy then during each follow up visit. RESULTS: Demographic and patients' characteristics were comparable between the 2 arms. The dose to different organs at risk were statistically lower in the SVCI arm. 2-year local control rate was 100% in SVCI arm and 96% in the whole larynx arm, with no significant difference. No grade 3 or 4 toxicities were reported in both treatment arms. Patients in the SVCI arm demonstrated lower VHI scores at 2‚ÄØmonths and 1-year post-treatment, with median scores of 4 and 0, respectively, compared with 22 and 21 in the whole-larynx arm. CONCLUSION: SVCI is effective and safe treatment for T1aN0 glottic cancer with comparable local control rates and safe toxicity profile. SVCI was associated with superior voice outcome as evidenced by significantly improved VHI scores compared with whole larynx radiotherapy.</description>
    </item>
    <item>
      <title>#7 [70/100] Improved Survival of HPV-Related Sinonasal Squamous Cell Carcinoma With Chemoradiation Treatment.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41503790/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41503790/</guid>
      <dc:creator>Oliver JR, Wang NC, Alapati R, Attwood E, Amanian A, Bur AM, Beahm DD</dc:creator>
      <pubDate>Thu, 08 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study utilizes a large dataset from the National Cancer Database to analyze treatment outcomes in HPV-related sinonasal squamous cell carcinoma, providing important insights into survival differences, though it is a retrospective analysis rather than a randomized controlled trial.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Oliver JR, Wang NC, Alapati R, Attwood E, Amanian A, Bur AM, Beahm DD&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Head &amp; neck | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/hed.70156'&gt;10.1002/hed.70156&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-08&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41503790/'&gt;41503790&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;OBJECTIVE: Human papillomavirus-related (HPV+) sinonasal squamous cell carcinoma (SNSCC) is associated with improved overall survival (OS) compared to similarly staged HPV-negative SNSCC. However, data on treatment-specific outcomes remain limited. METHODS: We analyzed the National Cancer Database (NCDB) for all SNSCC cases diagnosed between 2010 and 2017 with available HPV testing data. Prognostically significant variables were identified via multivariable Cox regression. Propensity score-matched cohorts were then created, matching HPV-positive and HPV-negative patients exactly by treatment modality and other significant prognostic factors. The association between HPV status and 5-year OS was assessed across treatment strategies. RESULTS: A total of 1697 HPV-tested SNSCC cases were identified; 551 (32.5%) were HPV+. Multivariable Cox regression showed that HPV status, age, comorbidity score, tumor size, lymphovascular invasion, stage, and surgical margin status were significantly associated with outcomes. Within the propensity score-matched cohort, HPV positivity was significantly associated with improved OS among patients treated with chemoradiation (HR‚Äâ=‚Äâ0.55; 95% CI‚Äâ=‚Äâ0.35-0.87, p‚Äâ=‚Äâ0.01). No survival benefit was observed in patients treated with surgery alone (HR‚Äâ=‚Äâ0.85; 95% CI‚Äâ=‚Äâ0.35-2.04, p‚Äâ=‚Äâ0.71), surgery with radiation (HR‚Äâ=‚Äâ1.38; 95% CI‚Äâ=‚Äâ0.64-3.02, p‚Äâ=‚Äâ0.41), radiation alone (HR‚Äâ=‚Äâ0.40; 95% CI‚Äâ=‚Äâ0.11-1.41, p‚Äâ=‚Äâ0.16), or in the combined group of these three treatment strategies (HR‚Äâ=‚Äâ0.97; 95% CI‚Äâ=‚Äâ0.57-1.62, p‚Äâ=‚Äâ0.90). CONCLUSION: These findings suggest that HPV+ SNSCC may be particularly sensitive to chemoradiation. Routine HPV testing may be warranted to investigate if tailored treatment approaches focusing on chemoradiation may benefit patients with HPV+ SNSCC.</description>
    </item>
    <item>
      <title>#8 [70/100] A seven-gene 5-hydroxymethylcytosine signature in circulating cell-free DNA for prognostic stratification of nasopharyngeal carcinoma.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41500466/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41500466/</guid>
      <dc:creator>Chen B, Wang D, Huang J, Yu S, Fang S, Chen C, Wang J, Pan J, Lin S, Guo Q, et al.</dc:creator>
      <pubDate>Mon, 05 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study presents a novel prognostic biomarker based on a seven-gene signature in circulating cfDNA for nasopharyngeal carcinoma, utilizing a reasonably sized cohort and rigorous methodology, which could have important clinical implications for patient stratification.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Chen B, Wang D, Huang J, Yu S, Fang S, Chen C, Wang J, Pan J, Lin S, Guo Q, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.radonc.2026.111366'&gt;10.1016/j.radonc.2026.111366&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-05&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41500466/'&gt;41500466&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND: Circulating cell-free DNA (cfDNA) 5-hydroxymethylcytosine (5hmC) is a promising epigenetic biomarker in cancer. Its prognostic role in nasopharyngeal carcinoma (NPC), however, remains unclear. METHODS: Genome-wide 5hmC profiling was conducted using 5hmC-Seal sequencing on cfDNA from 174 newly diagnosed NPC patients. Patients were randomly assigned to training (n‚ÄØ=‚ÄØ105) and test (n‚ÄØ=‚ÄØ69) sets. Differential analysis was performed by survival outcome, EBV status, and tumor stage. The primary endpoint was overall survival (OS); the secondary endpoint was event-free survival (EFS). A prognostic score based on a seven-gene 5hmC signature was developed using LASSO-Cox regression in the training set and validated in the test cohort. A nomogram integrating the 5hmC score, tumor stage, and EBV status was constructed. Model performance was assessed via Kaplan-Meier survival analysis, time-dependent ROC curves, calibration plots, and decision curve analysis (DCA). RESULTS: Marked 5hmC differences were detected between survivors and non-survivors. The 5hmC score stratified OS with AUCs of 0.83 (3-year) and 0.87 (5-year) in the training set and 0.78 (3-year) and 0.80 (5-year) in the test set, and remained predictive across EBV and stage subgroups. The integrated nomogram demonstrated robust calibration and offered the greatest net clinical benefit in DCA, with a 5-year C-index of 0.796. CONCLUSIONS: cfDNA 5hmC profiling enables noninvasive prognostic risk stratification in NPC. The proposed model may support personalized treatment planning and long-term management.</description>
    </item>
    <item>
      <title>#9 [65/100] Prognostic significance of p16 and immune cell infiltration in recurrent/metastatic head and neck squamous cell carcinoma treated with PD-1 inhibition: a national DAHANCA cohort study.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41529587/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41529587/</guid>
      <dc:creator>S√∏by S, Mortensen D, Gothelf A, Gyldenkerne N, Maare C, Lonkvist CK, Andersen M, Kjeldsen R, Toustrup K, Tramm T, et al.</dc:creator>
      <pubDate>Mon, 12 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;üìå SELECTED - Score: 65/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study is a large multicenter retrospective cohort analysis focusing on prognostic biomarkers in a real-world setting for patients treated with PD-1 inhibitors, which provides important insights but lacks the definitive evidence and practice-changing findings characteristic of higher-impact studies.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; S√∏by S, Mortensen D, Gothelf A, Gyldenkerne N, Maare C, Lonkvist CK, Andersen M, Kjeldsen R, Toustrup K, Tramm T, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Oral oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.oraloncology.2026.107849'&gt;10.1016/j.oraloncology.2026.107849&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-12&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41529587/'&gt;41529587&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;PD-1 inhibition has become an established treatment option for recurrent/metastatic head and neck squamous cell carcinoma (rmHNSCC). However, there is a clear need for improved prognostic tools. This study aimed to identify immune-related tissue biomarkers associated with overall survival (OS) or progression-free survival (PFS) in patients treated with PD-1 inhibition. This national real-world phase IV multicenter retrospective cohort study included Danish patients treated between 2017 and 2023. Pre-treatment biopsies were collected for immunohistochemical analyses. All patients were PD-L1 positive with histologically confirmed rmHNSCC treated with pembrolizumab or nivolumab monotherapy. Biomarker expression was assessed for CD4, CD8, FOXP3, CD20, CD66b, CD68, STING, cGAS, and tumor-infiltrating lymphocytes (TILs), using the median expression as the cut-off value. Formalin-fixed, paraffin-embedded tumor tissue was obtained from 263 eligible patients. Concurrent above median levels of FOXP3 and CD68 were associated with a lower risk of progression (HRPFS: 0.47 [95¬†% CI: 0.33-0.67]). This interaction appeared to be driven by p16+ oropharyngeal cancers (OPC), where patients with concurrent above median levels of FOXP3 and CD68 showed a median 2-year PFS of 68¬†% [95¬†% CI: 42-86] in contrast to those with one or none of the two markers above the median level with a 2-year PFS of 3¬†% [95¬†% CI: 0-12] (p¬†&lt;¬†0.001). In this real-world cohort, a subgroup with a promising prognosis was identified. This subgroup was characterized by p16+ OPC along with concurrent above median levels of FOXP3 and CD68. PD-L1 alone showed no significant association with outcomes.</description>
    </item>
    <item>
      <title>#10 [65/100] Age-Related Risk Stratification in HPV-Positive Oropharyngeal Cancer: Implications for Treatment De-Intensification.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41525711/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41525711/</guid>
      <dc:creator>Zhang C, Cheng Z, Jiang X, Zhao G, Zhu Y, Hou B, Sun Y, Liang S, Zhang Y, Wang Z, et al.</dc:creator>
      <pubDate>Mon, 12 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;üìå SELECTED - Score: 65/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study utilizes a large dataset to explore age-related risk stratification in HPV-positive oropharyngeal cancer, which may inform treatment de-intensification strategies, but it is based on retrospective data and does not present practice-changing findings.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Zhang C, Cheng Z, Jiang X, Zhao G, Zhu Y, Hou B, Sun Y, Liang S, Zhang Y, Wang Z, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Head &amp; neck | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/hed.70167'&gt;10.1002/hed.70167&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-12&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41525711/'&gt;41525711&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND: Although the AJCC eighth edition staging system incorporates HPV status, it remains insufficient to guide personalized treatment in HPV-positive oropharyngeal cancer (OPC). This study aimed to identify the optimal age threshold and evaluate its association with overall survival (OS) to improve risk stratification and inform individualized treatment strategies. METHODS: Data were extracted from the SEER database (2018-2021), the University Health Network (UHN), University of Toronto, and the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences (NCC). Only HPV-positive OPC cases with complete survival records were included. The optimal age threshold was identified using restricted cubic spline modeling in combination with a recursive partitioning approach. Prognostic factors beyond HPV status and AJCC eighth edition stage were evaluated using multivariable Cox proportional hazards models. Recursive partitioning analysis (RPA) was used to construct a risk stratification model. The primary endpoint was OS. RESULTS: Of the 10‚Äâ283 eligible patients (87.9% male; median age, 62‚Äâyears), 2.7% had distant metastases at diagnosis. Restricted cubic spline analysis revealed that 62‚Äâyears of age represents an important critical threshold. Multivariable Cox analysis revealed that patients younger than 62‚Äâyears exhibited significantly improved OS (HR, 0.61; 95% CI, 0.54-0.70; p‚Äâ&lt;‚Äâ0.001). RPA stratified patients into five risk groups with distinct 2-year OS: extremely low (96.8%), low (93.7%), intermediate (86.1%), high (74.6%), and extremely high risk (47.5%). Among patients classified in the extremely low-risk group (T0-2N0-1M0 and younger than 62‚Äâyears), no significant difference in OS was observed between those treated with radiotherapy alone and those treated with chemoradiotherapy. External validation in the UHN (N‚Äâ=‚Äâ843) and NCC (N‚Äâ=‚Äâ167) cohorts suggested that extremely low-risk patients might be spared concurrent chemotherapy. CONCLUSIONS: This study developed a risk stratification model for patients with p16-positive OPC based on the AJCC eighth edition staging and age. Patients in the extremely low-risk group may derive limited benefit from concurrent chemotherapy, suggesting that its omission could be considered in selected patients and may help guide the design of future de-escalation trials.</description>
    </item>
  </channel>
</rss>
